Shopping Cart 0
Cart Subtotal
AED 0

ALK-Abello AS (ALK B)-Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 1376

Details

ALK-Abello AS (ALK B)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ALK-Abello A/S (ALK) is a research-oriented pharmaceutical company, which discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It also markets diagnostics and other services to allergy clinics. The company's allergy immunotherapy product portfolio includes tablet-based vaccines, sublingual or drop-based vaccines, subcutaneous vaccines; and adrenaline auto-injector to treat severe allergic reactions in emergencies (anaphylaxis). ALK's research and development pipeline products include sublingual immunotherapy tablets for addressing the ragweed, house dust mite and tree pollen allergy. The company's products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, dog, venom and cat, among others. It has subsidiaries in Europe, North America, Asia-Pacific and other international markets. ALK is headquartered in Horsholm, Denmark.

ALK-Abello AS Key Recent Developments

Mar 03, 2017: ALK Appoints SVP of R&D for North America and International Markets

Feb 07, 2017: ALK releases its annual report 2016

Jan 10, 2017: Carsten Hellmann joins ALK as new President and CEO

Jan 04, 2017: ALK upgrades its full-year 2016 financial outlook following better than expected Q4 sales

Nov 10, 2016: ALK-Abello: Nine-month interim report (Q3) 2016

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

ALK-Abello A/S-Key Facts 6

ALK-Abello A/S-Key Employees 7

ALK-Abello A/S-Key Employee Biographies 8

ALK-Abello A/S-Major Products and Services 9

ALK-Abello A/S-Pharmaceutical Pipeline Products Data 10

ALK-Abello A/S, Pipeline Products by Therapy Area 10

ALK-Abello A/S, Pipeline Products by Development Phase 11

ALK-Abello A/S-History 12

ALK-Abello A/S-Company Statement 15

ALK-Abello A/S-Locations And Subsidiaries 16

Head Office 16

Other Locations & Subsidiaries 16

Section 2-Company Analysis 18

ALK-Abello A/S-Business Description 18

ALK-Abello A/S-Corporate Strategy 19

ALK-Abello A/S-SWOT Analysis 20

SWOT Analysis-Overview 20

ALK-Abello A/S-Strengths 20

ALK-Abello A/S-Weaknesses 21

ALK-Abello A/S-Opportunities 22

ALK-Abello A/S-Threats 23

ALK-Abello A/S-Key Competitors 24

Section 3-Company Financial Ratios 25

Financial Ratios-Capital Market Ratios 25

Financial Ratios-Annual Ratios 26

Performance Chart 28

Financial Performance 28

Financial Ratios-Interim Ratios 29

Financial Ratios-Ratio Charts 30

Section 4-Company's Lifesciences Financial Deals and Alliances 31

ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31

ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32

ALK-Abello A/S, Recent Deals Summary 33

Section 5-Company's Recent Developments 34

Mar 03, 2017: ALK Appoints SVP of R&D for North America and International Markets 34

Feb 07, 2017: ALK releases its annual report 2016 35

Jan 10, 2017: Carsten Hellmann joins ALK as new President and CEO 36

Jan 04, 2017: ALK upgrades its full-year 2016 financial outlook following better than expected Q4 sales 37

Nov 10, 2016: ALK-Abello: Nine-month interim report (Q3) 2016 38

Aug 16, 2016: ALK-Abello: Six-month interim report (Q2) 2016 39

May 17, 2016: ALK appoints Carsten Hellmann as new President and CEO 40

May 04, 2016: ALK-Abello: Three-month interim report 2016 41

Feb 22, 2016: ALK's CEO Jens Bager steps down 42

Feb 09, 2016: ALK releases its annual report 2015 43

Section 6-Appendix 44

Methodology 44

Ratio Definitions 44

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

ALK-Abello A/S, Pipeline Products by Therapy Area 10

ALK-Abello A/S, Pipeline Products by Development Phase 11

ALK-Abello A/S, Performance Chart (2012-2016) 28

ALK-Abello A/S, Ratio Charts 30

ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31

ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 32


List Of Table

List of Tables

ALK-Abello A/S, Key Facts 6

ALK-Abello A/S, Key Employees 7

ALK-Abello A/S, Key Employee Biographies 8

ALK-Abello A/S, Major Products and Services 9

ALK-Abello A/S, Number of Pipeline Products by Therapy Area 10

ALK-Abello A/S, Number of Pipeline Products by Development Stage 11

ALK-Abello A/S, History 12

ALK-Abello A/S, Subsidiaries 16

ALK-Abello A/S, Key Competitors 24

ALK-Abello A/S, Ratios based on current share price 25

ALK-Abello A/S, Annual Ratios 26

ALK-Abello A/S (Cont...1), Annual Ratios 27

ALK-Abello A/S, Interim Ratios 29

ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31

ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32

ALK-Abello A/S, Recent Deals Summary 33

Currency Codes 44

Capital Market Ratios 44

Equity Ratios 45

Profitability Ratios 45

Cost Ratios 46

Liquidity Ratios 46

Leverage Ratios 46

Efficiency Ratios 47

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

ALK-Abello AS, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

UCB SA, Stallergenes Greer plc, Qualitest Pharmaceuticals, Allergy Therapeutics Plc, Allergopharma GmbH & Co KG

Company Profile

Company Profile Title

ALK-Abello AS (ALK B)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ALK-Abello A/S (ALK) is a research-oriented pharmaceutical company, which discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It also markets diagnostics and other services to allergy clinics. The company's allergy immunotherapy product portfolio includes tablet-based vaccines, sublingual or drop-based vaccines, subcutaneous vaccines; and adrenaline auto-injector to treat severe allergic reactions in emergencies (anaphylaxis). ALK's research and development pipeline products include sublingual immunotherapy tablets for addressing the ragweed, house dust mite and tree pollen allergy. The company's products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, dog, venom and cat, among others. It has subsidiaries in Europe, North America, Asia-Pacific and other international markets. ALK is headquartered in Horsholm, Denmark.

ALK-Abello AS Key Recent Developments

Mar 03, 2017: ALK Appoints SVP of R&D for North America and International Markets

Feb 07, 2017: ALK releases its annual report 2016

Jan 10, 2017: Carsten Hellmann joins ALK as new President and CEO

Jan 04, 2017: ALK upgrades its full-year 2016 financial outlook following better than expected Q4 sales

Nov 10, 2016: ALK-Abello: Nine-month interim report (Q3) 2016

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

ALK-Abello A/S-Key Facts 6

ALK-Abello A/S-Key Employees 7

ALK-Abello A/S-Key Employee Biographies 8

ALK-Abello A/S-Major Products and Services 9

ALK-Abello A/S-Pharmaceutical Pipeline Products Data 10

ALK-Abello A/S, Pipeline Products by Therapy Area 10

ALK-Abello A/S, Pipeline Products by Development Phase 11

ALK-Abello A/S-History 12

ALK-Abello A/S-Company Statement 15

ALK-Abello A/S-Locations And Subsidiaries 16

Head Office 16

Other Locations & Subsidiaries 16

Section 2-Company Analysis 18

ALK-Abello A/S-Business Description 18

ALK-Abello A/S-Corporate Strategy 19

ALK-Abello A/S-SWOT Analysis 20

SWOT Analysis-Overview 20

ALK-Abello A/S-Strengths 20

ALK-Abello A/S-Weaknesses 21

ALK-Abello A/S-Opportunities 22

ALK-Abello A/S-Threats 23

ALK-Abello A/S-Key Competitors 24

Section 3-Company Financial Ratios 25

Financial Ratios-Capital Market Ratios 25

Financial Ratios-Annual Ratios 26

Performance Chart 28

Financial Performance 28

Financial Ratios-Interim Ratios 29

Financial Ratios-Ratio Charts 30

Section 4-Company's Lifesciences Financial Deals and Alliances 31

ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31

ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32

ALK-Abello A/S, Recent Deals Summary 33

Section 5-Company's Recent Developments 34

Mar 03, 2017: ALK Appoints SVP of R&D for North America and International Markets 34

Feb 07, 2017: ALK releases its annual report 2016 35

Jan 10, 2017: Carsten Hellmann joins ALK as new President and CEO 36

Jan 04, 2017: ALK upgrades its full-year 2016 financial outlook following better than expected Q4 sales 37

Nov 10, 2016: ALK-Abello: Nine-month interim report (Q3) 2016 38

Aug 16, 2016: ALK-Abello: Six-month interim report (Q2) 2016 39

May 17, 2016: ALK appoints Carsten Hellmann as new President and CEO 40

May 04, 2016: ALK-Abello: Three-month interim report 2016 41

Feb 22, 2016: ALK's CEO Jens Bager steps down 42

Feb 09, 2016: ALK releases its annual report 2015 43

Section 6-Appendix 44

Methodology 44

Ratio Definitions 44

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

ALK-Abello A/S, Pipeline Products by Therapy Area 10

ALK-Abello A/S, Pipeline Products by Development Phase 11

ALK-Abello A/S, Performance Chart (2012-2016) 28

ALK-Abello A/S, Ratio Charts 30

ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31

ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 32


List Of Table

List of Tables

ALK-Abello A/S, Key Facts 6

ALK-Abello A/S, Key Employees 7

ALK-Abello A/S, Key Employee Biographies 8

ALK-Abello A/S, Major Products and Services 9

ALK-Abello A/S, Number of Pipeline Products by Therapy Area 10

ALK-Abello A/S, Number of Pipeline Products by Development Stage 11

ALK-Abello A/S, History 12

ALK-Abello A/S, Subsidiaries 16

ALK-Abello A/S, Key Competitors 24

ALK-Abello A/S, Ratios based on current share price 25

ALK-Abello A/S, Annual Ratios 26

ALK-Abello A/S (Cont...1), Annual Ratios 27

ALK-Abello A/S, Interim Ratios 29

ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31

ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32

ALK-Abello A/S, Recent Deals Summary 33

Currency Codes 44

Capital Market Ratios 44

Equity Ratios 45

Profitability Ratios 45

Cost Ratios 46

Liquidity Ratios 46

Leverage Ratios 46

Efficiency Ratios 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

ALK-Abello AS, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

UCB SA, Stallergenes Greer plc, Qualitest Pharmaceuticals, Allergy Therapeutics Plc, Allergopharma GmbH & Co KG